Agentix Corp.

Agentix Corp.

AGTX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.35M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Agentix Corp.Agentix Corp.-3.7-10%--
$-0.01

Current Fair Value

126.2% downside

Overvalued by 126.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.35 Million
Enterprise Value$1.35 Million
Earnings per Share$-0.01
Beta0.77
Outstanding Shares40,066,951

Return

Return on Equity9.57%ROE
Return on Assets-27774.70%
Return on Invested Capital7.50%

Valuation & Multiples

P/E Ratio-3.7P/E Ratio
PEG10.05PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.03Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-4.73
Enterprise Value to Net Income-4
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 6, 2026
EPS
-$0.00
Reported
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Agentix Corp.

2 employees
CEO: Riazul Huda

Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a periph...